Skip to main content
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc — Investor Relations & Filings

Ticker · PTGX ISIN · US74366E1029 US Manufacturing
Open in API
Filings indexed 641 across all filing types
Latest filing 2018-12-31 Regulatory Filings
Country US United States of America
Listing US PTGX

About Protagonist Therapeutics, Inc

https://www.protagonist-inc.com/

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of peptide-based new chemical entities. The company utilizes its proprietary technology platform to engineer novel oral and injectable peptide therapeutics. Its development pipeline is focused on creating treatments for rare and prevalent diseases, particularly in the areas of hematology and gastroenterology, addressing significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement involving exchange of shares for warrants, unregistered sales of equity securities, and changes in senior management (departure of CFO and appointment of interim officers). There are no financial statements or detailed financial performance data included, only announcements of corporate events and agreements. This matches the characteristics of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories. The document length is 8844 characters, which is substantial but the content is primarily event announcements rather than a full report or financial data. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-12-31 English
SCHEDULE 13G
Major Shareholding Notification
2018-12-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 27, 2018. It announces a press release about a new development candidate and a conference call with an accompanying presentation. The document explicitly states it is a Current Report on Form 8-K and includes Regulation FD Disclosure. The content is an announcement of events and disclosures rather than a full financial report or earnings release. The document length is 4162 characters, which is relatively short and consistent with an 8-K filing. The document does not contain detailed financial statements or substantive financial data, so it is not an Interim/Quarterly Report or Annual Report. It is not a call transcript but mentions a conference call and presentation. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other categories.
2018-11-27 English
10-Q
Interim / Quarterly Report Q3 2018
2018-11-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 6, 2018, reporting the financial results for the quarter ended September 30, 2018. It specifically references a press release titled 'Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update' as an exhibit. The document is relatively short (4046 characters) and primarily serves to announce the earnings release and provide the press release as an exhibit. There are no detailed financial statements or substantive financial data within the text itself, only a summary and reference to the press release. According to the classification rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). This document fits that description as it announces quarterly results and includes a press release with financial highlights.
2018-11-06 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 22, 2018, for Protagonist Therapeutics, Inc. It includes a Regulation FD Disclosure under Item 7.01, stating that a presentation (Exhibit 99.1) is attached and intended for use on the same date. The text explicitly mentions that the information is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act, indicating it is a current report disclosing a presentation event. The document length is 3654 characters, which is relatively short and consistent with an announcement rather than a full report. The key content is a presentation for investors, as indicated by the description of Exhibit 99.1 as a presentation. Therefore, the document is best classified as an Investor Presentation (IP).
2018-10-22 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.